Relative to Alzheimer’s Disease and Brain Awareness Month.
ACR 222 is a nonbinding Assembly Concurrent Resolution that declares June 2026 as Alzheimer’s Disease and Brain Awareness Month in California and urges Californians to observe the month accordingly. The resolution frames Alzheimer’s disease as a major public health issue, emphasizing the scale of the disease in California, the burden on families and caregivers, and the need for greater awareness, diagnosis, and support services.
The measure does not create a new program, mandate state action, or change eligibility for benefits. Instead, it serves as a formal legislative recognition of Alzheimer’s disease and brain health, and it directs the Chief Clerk to transmit copies of the resolution for distribution. Its practical effect is symbolic and educational, intended to encourage public attention to brain health, dementia risk, and research efforts.
ACR 222 has no fiscal effect and does not amend the California Codes or impose regulatory requirements on state agencies, local governments, health care providers, or private parties. Its impact is limited to a legislative declaration and public awareness campaign, with the main affected groups being Californians living with Alzheimer’s disease, their caregivers, public health advocates, and organizations involved in dementia research and support services.
The overall sentiment around the resolution is strongly supportive and commemorative. The bill text presents Alzheimer’s disease as a serious and growing public health challenge and uses the resolution to highlight the need for awareness, prevention-oriented brain health messaging, and support for affected families. No opposing views or recorded committee controversy appear in the provided materials, and the bill advanced from committee to third reading without noted dissent.
There is little apparent contention in the available record because the measure is a ceremonial resolution rather than a policy bill. The only substantive emphasis in the text is on the scale of Alzheimer’s disease, the disproportionate impact on communities of color, and the need for better diagnosis and caregiver support. If any point of debate were to arise, it would likely concern whether symbolic resolutions meaningfully advance public health goals, but no such objection is reflected in the provided discussion or vote history.